Aprea reports Q3 net loss $3.2M; cash $25.4M; ATRN-1051 IND on track for Q4 2023

Aprea Therapeutics, Inc.

2023-Q3 EPS reported -$3.03

Net loss of $3.2M ($0.86/sh) vs $4.0M ($2.32/sh) in Q3 2022; operating loss reduced to $3.5M.
Cash and equivalents $25.4M as of Sep 30, 2023; cash runway through Q4 2024.
ATRN-119 dose escalation at cohort 4 (350mg); dose expansion enrollment expected Q2 2024.
ATRN-1051 IND submission planned Q4 2023 with clearance Q1 2024; Phase 1/2a start H1 2024.
R&D expenses $2.1M (up from $1.1M) due to ATRN-1051 IND studies; G&A down to $1.7M.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

Aprea Therapeutics, Inc. reported three and nine months ended September 30, 2023 results: net income a net loss of $3.2 million ($0.86 per basic share), EPS ($0.86 per basic share).

Period: three and nine months ended September 30, 2023
Net income: a net loss of $3.2 million ($0.86 per basic share)
EPS: ($0.86 per basic share)
Result: reported results

Exact text from the filing

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018581

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.